Akebia Therapeutics, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Akebia Therapeutics, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Akebia Therapeutics, Inc. zu Deinem Portfolio hinzuzufügen.
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 204,163 shares of Akebia's common stock on September 30, 2025. The options were granted as an inducement material to each emplo...
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Nicholas Grund - Senior VP & Chief Commercial Officer Presentation Unknown Analyst Good morning and thank you for joining us here today at the Wells Fargo Healthcare Conference. I'm join...
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 95,100 shares of Akebia's common stock on August 29, 2025. The options were granted as an inducement material to each employee...
I'm bullish on Akebia at $3.13, viewing the 21% post-earnings dip as a buying opportunity ahead of major revenue catalysts. Vafseo's rapid adoption and DaVita's pilot could double Akebia's addressable dialysis market, driving significant near-term revenue growth and profitability. Despite a mixed EPS, strong topline growth and stable Auryxia sales highlight Akebia's transition from speculative ...
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C.
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director Mercedes Carrasco - Senior Director of Investor & Corporate Communications Nicholas Grund - Senior VP & Chief Commercial Officer Conference Call Participants Ju...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.